Galectin Therapeutics Inc.
GALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $80 | $100 | $67 | $121 |
| - Cash | $15 | $26 | $19 | $40 |
| + Debt | $106 | $72 | $40 | $29 |
| Enterprise Value | $172 | $146 | $88 | $111 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$41 | -$38 | -$38 | -$30 |
| % Margin | – | – | – | – |
| Net Income | -$47 | -$41 | -$39 | -$31 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.76 | -0.74 | -0.65 | -0.52 |
| % Growth | -2.7% | -13.8% | -25% | – |
| Operating Cash Flow | -$42 | -$33 | -$31 | -$24 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$42 | -$33 | -$31 | -$24 |